Name layer
5-MeO-DMT is a short-acting tryptamine and the shorthand most readers recognize. In current drug-development coverage, SCM treats it as the compound-family layer, not as a substitute for a company program, formulation, route, indication, or clinical result.
That distinction matters because the same compound neighborhood can include different assets. GH001 and BPL-003 belong in the same map, but they are not interchangeable.
Program map
GH001 is GH Research’s inhaled mebufotenin program. BPL-003 is Beckley Psytech’s intranasal 5-MeO-DMT benzoate program. Results, regulatory language, and registry records should stay attached to the specific asset that generated them.
Use mebufotenin when the source uses that compound-name language, especially in the GH001 / JAMA Psychiatry evidence spine. Use 5-MeO-DMT when discussing the broader chemical shorthand or cross-program family resemblance.
SCM reading rule
Do not write as if a clinical result for one 5-MeO-DMT-family program proves the same thing for every other program. Keep the layers separate: compound, formulation, route, sponsor, trial record, indication, and evidence tier.
Historical toad or Albert Most material can be naming/context background. It is not clinical evidence for GH001, BPL-003, or any modern development program.